Beta-Amyloid 1-42 - a major component of amyloid plaques
Sequential proteolytic cleavage of the Amyloid Precursor Protein (APP) by secretases (α, β, γ) generates beta-Amyloid peptide fragments, of which beta-Amyloid 1-42 forms a major component of amyloid plaques in neurons of Alzheimer’s disease (AD) brains.
Researchers have used our beta-Amyloid 1-42 peptide in a range of studies including characterization of Aβ monomers, oligomers and fibrils; in vitro cell culture and transgenic animal models to determine Aβ induced neurotoxicity; influence of metal ions or autophagy in mediating neurotoxicity; inhibitors/analogues and antibodies directed against Aβ secretion, aggregation etc., as part of ongoing efforts to advance research and development of therapeutic agents against AD.
We offer one of the largest collections of beta-Amyloid 1-42 peptides, including native and modified sequences, and specialized formulations, featuring our Aggresure™ and GMP grade (for in vitro use) beta-Amyloid 1-42. In addition, we provide a variety of fluorescently labeled peptides including those labeled with our HiLyte™ Fluor 488, HiLyte™ Fluor 555, and HiLyte™ Fluor 647 dyes. For your convenience, we also synthesize large single batches of native beta-Amyloid 1-42 with high purity.
Selecting the most appropriate product depends on the application
- Our basic beta-Amyloid 1-42 is produced using proprietary chemistries and is released on two criteria only (mass and purity)
- For aggregation studies, we recommend using the pre-treated Aggresure™ beta-Amyloid 1-42. This is a proprietary pre-treatment allowing us to guarantee that the peptide will fibrillate and work in our Thioflavin T assay
- Should a non-treated but monomeric peptide be used, we recommend our GMP grade peptide